BKEVER试验:肾移植受者BK多瘤病毒感染中依维莫司与霉酚酸酯的比较
BKEVER随机多中心对照试验纳入130例BKPyV DNA血症肾移植受者,1:1分为依维莫司组(替换MMF并降低钙调神经磷酸酶抑制剂谷浓度)与MMF减半组。主要终点为6个月病毒清除率,依维莫司组55.7%显著低于MMF组81.3%,且MMF组BKPyV DNA载量下降更快。
要点
- 依维莫司替换MMF未提高6个月BKPyV清除率,反而低于MMF减半组。
- MMF组BKPyV DNA载量下降速度显著更快。
- 两组钙调神经磷酸酶抑制剂谷浓度无 meaningful 差异。
核心结论
- 在BKPyV DNA血症肾移植受者中,以依维莫司替换MMF并降低钙调神经磷酸酶抑制剂水平未导致更频繁或更快的BKPyV清除。
研究设计与样本
- 随机、多中心、对照试验(BKEVER研究),纳入130例BKPyV DNA血症肾移植受者,1:1随机分组。
- 依维莫司组:MMF替换为依维莫司,并降低钙调神经磷酸酶抑制剂谷浓度;MMF组:MMF剂量减半,并类似降低钙调神经磷酸酶抑制剂水平。
- 主要终点为6个月时病毒清除的患者比例;次要终点包括BKPyV复制动力学、BKPyV相关肾病发生率、移植肾功能、移植肾排斥反应发生率及两年药物耐受性。
主要发现
- 6个月时BKPyV清除率:依维莫司组55.7%,MMF组81.3%。
- MMF组BKPyV DNA载量下降显著更快。
- 从随机化至第6个月,两组钙调神经磷酸酶抑制剂谷浓度均在预期目标范围内,无 meaningful 差异。
临床怎么用
- 对于BKPyV DNA血症的肾移植受者,采用依维莫司替换MMF联合降低钙调神经磷酸酶抑制剂的策略并未优于MMF减半方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The MTOR inhibitors have demonstrated antiviral properties, and prior non-randomized studies have suggested they may have a suppressive effect on BKPyV replication. Here, in this randomized, multicenter, controlled trial (BKEVER study), we sought to evaluate the impact of everolimus (EVR) in facilitating the clearance of BKPyV compared to simply reducing immunosuppression among kidney transplant recipients (KTRs). All together, 130 KTRs presenting with BKPyV DNAemia were randomized 1:1 into two groups. The EVR group, in which mycophenolate mofetil (MMF) was replaced by EVR along with a decrease in calcineurin inhibitor trough levels and secondly the MMF group, in which the MMF dose was decreased by half along with a similar lowering of calcineurin inhibitor levels. The primary endpoint was the proportion of patients achieving viral clearance at six months. Secondary endpoints included the kinetics of BKPyV replication over time, the incidence of BKPyV-associated nephropathy, kidney graft function, the incidence of kidney graft rejection, and medication tolerability over two years. Significantly, BKPyV clearance was achieved in 55.7% of patients in the EVR group compared to 81.3% of patients in the MMF group at six months. The reduction in BKPyV DNA load was significantly more rapid in the MMF group. Calcineurin inhibitor trough levels were within expected target ranges and did not differ meaningfully between the two groups from randomization through month six. Two grafts were lost, and four patients died. Eleven patients in the EVR group and six patients in the MMF group developed biopsy-proven BKPyV nephropathy. Thus, in KTRs with BKPyV DNAemia, replacing MMF with EVR along with lowering calcineurin inhibitor levels did not lead to more frequent or faster clearance of BKPyV.
引用
- Caillard S, Meyer N, Solis M, et al. Insights from the BKEVER Trial comparing everolimus versus mycophenolate mofetil for BK Polyomavirus infection in kidney transplant recipients. Kidney Int. 2024. PMID: 39490986. doi:10.1016/j.kint.2024.09.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。